Search research articles
Contact Us
Filters
Showing results (181-190 of 228) with videos related to
Page
of 23
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
July 9, 2019
The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study
Serena Di Cosimo, Tiziana Triulzi, Sara Pizzamiglio, et al.
Clinical Lung Cancer
|
January 9, 2019
Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial
Claudio Vernieri, Diego Signorelli, Giulia Galli, et al.
ESMO Open
|
September 29, 2020
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
Andrea Sartore-Bianchi, Sara Lonardi, Cosimo Martino, et al.
Nature Medicine
|
August 1, 2022
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
Andrea Sartore-Bianchi, Filippo Pietrantonio, Sara Lonardi, et al.
Clinical Lung Cancer
|
April 16, 2020
DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation
Arsela Prelaj, Giuseppe Lo Russo, Claudia Proto, et al.
The Lancet. Oncology
|
May 17, 2014
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial
Vanesa Gregorc, Silvia Novello, Chiara Lazzari, et al.
Nature Immunology
|
April 27, 2021
Heme catabolism by tumor-associated macrophages controls metastasis formation
Francesca Maria Consonni, Augusto Bleve, Maria Grazia Totaro, et al.
Cancers
|
December 11, 2019
EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort
Arsela Prelaj, Roberto Ferrara, Sara Elena Rebuzzi, et al.
Lancet (London, England)
|
November 23, 2025
Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial
Michele Reni, Marina Macchini, Giulia Orsi, et al.
The New England Journal of Medicine
|
March 29, 2018
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
Axel Grothey, Alberto F Sobrero, Anthony F Shields, et al.
Page
of 23
Search research articles
Search
Showing results (181-190 of 228) with videos related to
Sort By:
Page
of 23
European Journal of Cancer (Oxford, England : 1990)
|
July 9, 2019
The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study
Serena Di Cosimo, Tiziana Triulzi, Sara Pizzamiglio, et al.
Clinical Lung Cancer
|
January 9, 2019
Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial
Claudio Vernieri, Diego Signorelli, Giulia Galli, et al.
ESMO Open
|
September 29, 2020
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
Andrea Sartore-Bianchi, Sara Lonardi, Cosimo Martino, et al.
Nature Medicine
|
August 1, 2022
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
Andrea Sartore-Bianchi, Filippo Pietrantonio, Sara Lonardi, et al.
Clinical Lung Cancer
|
April 16, 2020
DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation
Arsela Prelaj, Giuseppe Lo Russo, Claudia Proto, et al.
The Lancet. Oncology
|
May 17, 2014
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial
Vanesa Gregorc, Silvia Novello, Chiara Lazzari, et al.
Nature Immunology
|
April 27, 2021
Heme catabolism by tumor-associated macrophages controls metastasis formation
Francesca Maria Consonni, Augusto Bleve, Maria Grazia Totaro, et al.
Cancers
|
December 11, 2019
EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort
Arsela Prelaj, Roberto Ferrara, Sara Elena Rebuzzi, et al.
Lancet (London, England)
|
November 23, 2025
Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial
Michele Reni, Marina Macchini, Giulia Orsi, et al.
The New England Journal of Medicine
|
March 29, 2018
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
Axel Grothey, Alberto F Sobrero, Anthony F Shields, et al.
Page
of 23